Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Immunai has raised $215.0M in total funding. The most recent round was Series B. The last funding was announced in October 2021.
Immunai's investors include 8VC, Catalio Capital Management, TLV Partners, Meron Capital, Alexandria Venture Investments.
Immunai is headquartered in New York, United States.
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Immunai is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunai — Funding & Investors." VCBacked, October 27, 2021, https://www.vcbacked.co/company/immunai. Accessed August 14, 2026.
VCBacked. (2021). Immunai — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immunai
{{cite web |title=Immunai — Funding & Investors |url=https://www.vcbacked.co/company/immunai |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated